Were Gloria Melanie’s Immunovant (IMVT) share sales discretionary trades?

No. The filing explains the sales were mandated “sell to cover” transactions to satisfy tax withholding from the vesting and settlement of restricted stock units. It specifically notes they do not represent discretionary trading decisions by the reporting officer.

Why did Immunovant’s (IMVT) COO sell shares related to restricted stock units?

The sale covered tax withholding obligations tied to 6,872 restricted stock units that vested on February 18, 2026. The company elected to satisfy these obligations through a mandatory “sell to cover” transaction instead of requiring a separate cash payment.

Immunovant (IMVT) COO executes 3,238-share sell-to-cover tax transaction

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Immunovant, Inc. Chief Operating Officer Gloria Melanie reported three open-market sales of common stock that together totaled 3,238 shares on February 25, 2026. The reported transactions were executed at weighted average prices of $26.98, $28.16, and $28.90 per share.

According to the footnotes, these shares were sold to cover tax withholding obligations arising from the vesting and settlement of 6,872 restricted stock units that vested on February 18, 2026. The filing states that the sales were mandated under a “sell to cover” arrangement and do not represent discretionary trading decisions by the officer.

Insider Trade Summary

Net Seller: 3,238 shares ($90,184)

Net Sell 3 txns

Insider Gloria Melanie

Role Chief Operating Officer

Sold 3,238 shs ($90K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,437	$26.98	$39K
Sale	Common Stock	859	$28.16	$24K
Sale	Common Stock	942	$28.90	$27K

Holdings After Transaction: Common Stock — 172,074 shares (Direct)

Footnotes (1)

On November 18, 2024, the holder was granted 109,956 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on November 20, 2024, of which 6,872 of these RSUs vested on February 18, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.66 - $27.60 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.67 - $28.61 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.70 - $29.13 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Form 4 Insider Transactions: What Each Field Means →

02/27/2026 - 04:07 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gloria Melanie

(Last)

(First)

(Middle)

C/O IMMUNOVANT, INC.

1000 PARK FORTY PLAZA, SUITE 210

(Street)

DURHAM

27713

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Immunovant, Inc. [ IMVT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/25/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/25/2026		S		1,437⁽¹⁾	D	$26.98⁽²⁾	172,074	D
Common Stock	02/25/2026		S		859⁽¹⁾	D	$28.16⁽³⁾	171,215	D
Common Stock	02/25/2026		S		942⁽¹⁾	D	$28.9⁽⁴⁾	170,273	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. On November 18, 2024, the holder was granted 109,956 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on November 20, 2024, of which 6,872 of these RSUs vested on February 18, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.66 - $27.60 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

3. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.67 - $28.61 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

4. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.70 - $29.13 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Remarks:

	/s/ Tiago Girao, attorney-in-fact for Melanie Gloria	02/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Immunovant (IMVT) report for Gloria Melanie?

Immunovant reported that Chief Operating Officer Gloria Melanie sold 3,238 shares of common stock on February 25, 2026. The filing states these were open-market sales tied to tax withholding obligations from recently vested restricted stock units.

At what prices were the Immunovant (IMVT) shares sold by the COO?

The Form 4 reports weighted average sale prices of $26.98, $28.16, and $28.90 per share. Footnotes add that individual trades occurred within price ranges between $26.66 and $29.13 per share on February 25, 2026.

How many Immunovant (IMVT) shares did the COO own after these sales?

After the reported February 25, 2026 transactions, the Form 4 shows Chief Operating Officer Gloria Melanie holding 170,273 shares at the final line. Earlier lines show 172,074 and 171,215 shares following each respective sale during that trading sequence.

What prior equity grant to Immunovant (IMVT) COO is referenced in the Form 4?

The footnotes state that on November 18, 2024, the holder was granted 109,956 restricted stock units, previously reported on a November 20, 2024 Form 4. A portion of these RSUs, 6,872 units, vested on February 18, 2026, triggering the tax-related share sales.